Indications
Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.
Composition
- Active substance
- rufinamide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Inovelon
- Active substance
- rufinamide
- ATC code
- N03AF03
- Group
- Nervous system
- Therapeutic area
- Epilepsy
- Marketing authorisation holder
- Eisai GmbH
- Status
- Authorised
- EU authorisation
- 16 Jan 2007
- EMA product number